To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
Age between 18 and 80 years old, and expected survival is longer than 3 months
Clinically or pathologically diagnosed as primary hepatocellular carcinoma
Disease progression assessed according to mRECIST criteria after PD-1/L1 antibody treatment
Child-Pugh score of liver function A/B (< 7)
Patients whose tumor lesions are not suitable for ablation as assessed by the surgeon
Tumor burden greater than ≥70%, or tumor is not suitable for mRECIST standard evaluation
Patients with chronic viral hepatitis (hepatitis B, hepatitis C) have a viral load greater than 10^4 before receiving treatment or do not continue to take antiviral drugs regularly
Pregnant patients